Filing Analysis
Organogenesis Holdings Inc. has entered into an At-the-Market (ATM) Sales Agreement with BTIG, LLC and Citizens JMP Securities, LLC to sell up to $75 million of its Class A common stock.
🚩 Red Flags
- Potential for immediate equity dilution for existing shareholders via ATM offering.
📋 Key Facts
- Entered into an At-the-Market (ATM) Sales Agreement on August 6, 2026.
- The offering is for an aggregate amount of up to $75,000,000 in Class A common stock.
- Agents: BTIG, LLC and Citizens JMP Securities, LLC.
- Commission rate: Up to 3.0% of the gross sales price per share.
- The sale is conducted under a previously effective S-3 shelf registration statement (filed August 8, 2024).
Organogenesis Holdings Inc. filed an 8-K to furnish its earnings press release for the fiscal second quarter ended June 30, 2026. The filing serves as a formal announcement of quarterly results and does not contain specific financial data within the text itself.
📋 Key Facts
- Report date: August 6, 2026
- Reporting period: Fiscal second quarter ended June 30, 2026
- The filing incorporates a press release via Exhibit 99.1 regarding results of operations and financial condition.
Organogenesis Holdings Inc. entered into lease amendments for its manufacturing and R&D facilities in Canton, MA, extending terms through 2034. The leases involve counterparties who are significant shareholders and/or board members of the company.
🚩 Red Flags
- Related-party transaction: Landlords (65 Dan Road SPE, LLC and Dan Road Associates, LLC) are owned by significant shareholders (Alan Ades, Albert Erani, Dennis Erani, and Glenn Nussdorf).
- Conflict of interest: Board members Mr. Nussdorf and Robert Ades have direct or indirect ties to the landlords/property owners.
📋 Key Facts
- Lease extensions for premises at 65 Dan Road and 150 Dan Road in Canton, MA.
- Current lease expiration (Dec 31, 2027) extended to Dec 31, 2032 (Second Renewal Term).
- Option for an additional two-year term ending Dec 31, 2034 (Third Renewal Term).
- Rent adjustments include a floor of 103% of the 2027 annual rent or fair market value, with subsequent 3% annual increases.
- The Audit Committee approved the transactions as being in the best interests of stockholders per company policy.
Organogenesis Holdings Inc. filed an 8-K to furnish its press release regarding the financial results for the fiscal third quarter ended September 30, 2025.
📋 Key Facts
- Report date: November 6, 2025
- Reporting period: Fiscal third quarter ended September 30, 2025
- The filing serves to furnish results of operations and financial condition via press release (Exhibit 99.1).
Organogenesis Holdings Inc. announced that its second Phase 3 randomized controlled trial (RCT) for ReNu, a treatment for knee osteoarthritis, failed to achieve statistical significance for its primary endpoint. While the drug showed numerical improvement and a favorable safety profile, it missed the required p-value threshold for regulatory success in this specific study.
🚩 Red Flags
- Failure of a primary endpoint in a pivotal Phase 3 clinical trial is a major setback for biotech/med-tech companies.
- The p-value (0.0393) missed the company's own target threshold (0.023), creating regulatory uncertainty.
📋 Key Facts
- The second Phase 3 RCT was a fully enrolled 594-patient trial comparing ReNu to a saline control.
- The study failed its primary endpoint: the p-value was 0.0393, which is higher than the target threshold of 0.023.
- ReNu demonstrated numerical improvement in baseline pain reduction at six months (-6.5 vs -6.0 in first trial).
- The company plans to request a pre-Biologics License Application (BLA) meeting with the FDA by late October 2025.
- Management intends to discuss using combined efficacy analysis from both Phase 3 studies to support BLA approval.
Organogenesis Holdings Inc. entered into a Fourth Amendment to its Credit Agreement with Silicon Valley Bank and other lenders. The amendment provides temporary relief for the Q2 2025 fixed charge coverage ratio covenant but mandates a full renegotiation of financial covenants by September 30, 2025.
🚩 Red Flags
- Mandatory renegotiation requirement: The company must reset financial covenants by Sept 30, 2025, or face default.
- Lender freeze: Lenders are not obligated to provide further revolving credit until new terms are agreed upon.
- Potential liquidity pressure: Requirement for 'pro forma compliance' for any additional borrowing could restrict capital access.
📋 Key Facts
- Entered into Fourth Amendment to Credit Agreement on August 5, 2025.
- Consolidated fixed charge coverage ratio covenant will not be tested for the fiscal quarter ending June 30, 2025, provided no swingline or revolving loans are outstanding.
- The Company must enter into an agreement to reset or implement new financial covenants by September 30, 2025.
- Lenders have no further obligation to make revolving extensions of credit until a new agreement is executed; failure to reach an agreement constitutes an event of default.
- Company expects cash on hand and net cash flows from sales to fund operations and debt service for at least 12 months beyond the Q2 2025 filing date.
Organogenesis Holdings Inc. reported the results of its 2025 Annual Meeting of Stockholders held on June 23, 2025. The meeting resulted in the election of several directors and approval of key shareholder proposals, including executive compensation and auditor ratification.
🚩 Red Flags
- Approval of potential 'change of control' via Series A conversion (Nasdaq Rule 5635(b)).
- Significant number of broker non-votes (34,035,738) across all proposals, indicating high level of undelivered or uninstructed shares.
📋 Key Facts
- Held 2025 Annual Meeting of Stockholders on June 23, 2025.
- Re-elected Garrett Lustig to the Board of Directors via written consent by Series A Convertible Preferred Stock holders.
- Elected nine directors: Robert Ades, Michael J. Driscoll, Prathyusha Duraibabu, Jon Giacomin, Gary S. Gillheeney, Sr., Michele Korfin, Arthur S. Leibowitz, Glenn H. Nussdorf, and Gilberto Quintero.
- Approved advisory compensation for named executive officers (67,071,290 votes in favor).
- Approved the issuance of up to 20% of Class A common stock upon conversion of Series A Convertible Preferred Stock at less than 'minimum price' per Nasdaq rules, potentially constituting a change of control.
- Ratified the appointment of RSM US LLP as independent auditor for fiscal year ending December 31, 2025.
Organogenesis Holdings Inc. filed an 8-K to furnish its press release regarding the financial results for the fiscal first quarter ended March 31, 2025.
📋 Key Facts
- Reporting period: Fiscal first quarter ended March 31, 2025.
- Filing date: May 8, 2025.
- The filing includes a press release (Exhibit 99.1) containing results of operations and financial condition.
Organogenesis Holdings Inc. filed an 8-K to disclose the posting of a new investor presentation on its website as part of Regulation FD disclosure.
📋 Key Facts
- The Company posted an Investor Presentation to its website on March 27, 2025.
- The presentation is attached as Exhibit 99.1 and is intended for information purposes under Regulation FD.
- The filing explicitly states the presentation is not 'filed' for purposes of Section 18 of the Exchange Act.
Organogenesis Holdings Inc. filed an 8-K to announce its financial results for the fiscal fourth quarter and full fiscal year ended December 31, 2024.
📋 Key Facts
- Reporting period: Fiscal fourth quarter and fiscal year ended December 31, 2024.
- Announcement date: February 27, 2025.
- The filing incorporates a press release via Exhibit 99.1 regarding results of operations and financial condition.
Organogenesis Holdings Inc. entered into a stock repurchase agreement to buy back 500,000 shares of Class A common stock from the GN 2016 Family Trust at $4.057 per share. The transaction involves a board member as a beneficial owner of the selling entity.
🚩 Red Flags
- Related-party transaction: The shares are being repurchased from an entity controlled by a Board member (Glenn H. Nussdorf).
- Potential use of capital: Using proceeds from recent preferred stock issuance to fund a share repurchase can sometimes be viewed as using new equity capital to exit existing shareholders.
📋 Key Facts
- Repurchase amount: 500,000 shares of Class A common stock.
- Purchase price: $4.057 per share (based on 10-day trailing VWAP as of Nov 26, 2024).
- Counterparty: GN 2016 Family Trust u/a/d August 12, 2016.
- Insider connection: Glenn H. Nussdorf, a member of the Board of Directors, is a beneficial owner of the shares held by the Selling Stockholder.
- Funding source: Proceeds from the Nov 12, 2024 sale of Series A Convertible Preferred Stock to Avista Healthcare Partners III, L.P. and AHP III Orchestra Holdings, L.P.
- Expected closing date: On or around December 3, 2024.
Organogenesis Holdings Inc. entered into a long-term triple net lease for approximately 122,000 square feet of manufacturing space in Smithfield, Rhode Island. The facility is intended to expand the company's production capacity.
🚩 Red Flags
- Triple net lease increases operational expense volatility as the company is responsible for taxes and operating expenses.
- Potential $1.25 million penalty if tax incentives are not secured by March 31, 2025.
- Risk of build-out delays or cost overruns mentioned in forward-looking statements.
📋 Key Facts
- Lease term: Approximately 16.5 years (Nov 18, 2024 – May 31, 2041) with two 10-year renewal options.
- Premises size: ~122,000 square feet at 100 Technology Way, Smithfield, RI.
- Rent structure: Triple net (NNN); base rent of $43.00/sq ft starting June 1, 2026, with a 3% annual increase thereafter.
- Build-out requirement: Company must complete build-out within 36 months; landlord to provide an allowance to offset costs.
- Termination clause: Right to terminate if certain state/local tax incentives are not secured by March 31, 2025 (penalty of $1.25M).
- Purchase option: Includes a one-time right of first offer to purchase the premises.
Organogenesis Holdings Inc. entered into a $130 million subscription agreement to issue 130,000 shares of Series A Convertible Preferred Stock to Avista Healthcare Partners III and an affiliate. The transaction includes a significant $23.5 million repurchase of common stock from existing directors/affiliates and requires the full prepayment of a $62.5 million term loan.
🚩 Red Flags
- Significant dilution potential due to high conversion ratio (263.7x).
- Related-party transactions: $23.5 million used to repurchase shares from directors and former directors.
- Complex capital structure change involving senior preferred stock with liquidation preference.
- Requirement to file registration statement within 40 days, indicating potential future dilution/selling pressure.
📋 Key Facts
- Total offering amount: $130.0 million for 130,000 shares of Series A Convertible Preferred Stock.
- Conversion ratio: Each share is initially convertible into 263.7358 shares of Common Stock.
- Stock Repurchase: $23.5 million to repurchase 7,421,731 shares of Class A common stock at $3.1597 per share from directors and affiliates.
- Debt Repayment: The company expects to prepay approximately $62.5 million in principal and interest on its Term Loan Facility on November 13, 2024.
- Board Change: Garrett Lustig appointed to the Board as a designee of the Investors; Board size increased to twelve directors.
- Placement Agent: Truist Securities, Inc. (4.0% cash fee).
Organogenesis Holdings Inc. filed an 8-K to furnish its press release regarding the financial results for the fiscal third quarter ended September 30, 2024.
📋 Key Facts
- Report date: November 12, 2024
- Reporting period: Fiscal third quarter ended September 30, 2024
- The filing incorporates a press release via Exhibit 99.1 regarding results of operations and financial condition.
Organogenesis Holdings Inc. filed an 8-K to furnish its press release announcing financial results for the fiscal second quarter ended June 30, 2024.
📋 Key Facts
- The filing pertains to the fiscal second quarter ended June 30, 2024.
- Results were announced via press release on August 8, 2024.
- The announcement is furnished under Item 2.02 and is not considered 'filed' for purposes of Section 18 liabilities.
Organogenesis Holdings Inc. reported the results of its 2024 Annual Meeting of Stockholders held on June 20, 2024. Shareholders approved several key items, including the election of directors and an amendment to increase shares reserved for the 2018 Equity Incentive Plan.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- Annual Meeting held on June 20, 2024, with 109,048,425 shares represented.
- Stockholders approved an amendment to the 2018 Equity Incentive Plan to increase reserved Class A common stock by 15,900,000 shares.
- Eleven directors were elected to serve until the next Annual Meeting.
- Shareholders approved the advisory 'Say-on-Pay' compensation for named executive officers (63,842,175 votes in favor).
- Stockholders ratified the appointment of RSM US LLP as independent auditors for fiscal year 2024.
Organogenesis Holdings Inc. filed an 8-K to announce its financial results for the fiscal first quarter ended March 31, 2024. The filing serves as a formal notice that the company's quarterly earnings press release is being furnished to the SEC.
📋 Key Facts
- Reporting period: Fiscal first quarter ended March 31, 2024.
- Filing date: May 9, 2024.
- The filing incorporates a press release (Exhibit 99.1) regarding results of operations and financial condition.
Organogenesis Holdings Inc. announced that a U.S. District Court has dismissed a securities fraud lawsuit against the company and its top executives with prejudice.
🚩 Red Flags
- None identified; this is a resolution of a legal liability rather than an emergence of one.
📋 Key Facts
- On March 29, 2024, the U.S. District Court for the Eastern District of New York granted a motion to dismiss all claims in a securities fraud case.
- The dismissal was granted 'with prejudice,' meaning the plaintiffs cannot refile the same claims.
- The lawsuit targeted Organogenesis Holdings Inc., its CEO, and its CFO.
Organogenesis Holdings Inc. filed an 8-K to announce its financial results for the fiscal fourth quarter and full year ended December 31, 2023. The filing serves as a formal mechanism to furnish the press release containing these earnings results.
📋 Key Facts
- Reporting period: Fiscal fourth quarter and year ended December 31, 2023.
- Filing date: February 29, 2024.
- The filing incorporates a press release via Exhibit 99.1 to communicate results of operations and financial condition.